No positive effect of rhdnase on the pulmonary colonization in children with cystic fibrosis

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 73, Issue 1, 2010, Pages 12-17

  Bonestroo, H J C ^a   Slieker, M G ^a   Arets, H G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cystic fibrosis; Pseudomonas aeruginosa; Pulmonary colonization; rhDNAse

Indexed keywords

AZITHROMYCIN; CEFUROXIME; COLISTIN; COTRIMOXAZOLE; DORNASE ALFA; TOBRAMYCIN;

ARTICLE; BACTERIAL COLONIZATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

EID: 77952728027     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: 10.4081/monaldi.2010.308     Document Type: Article

References (30)

1. Menzin J, Oster G, Davies L, et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Int J Technol Assess Health Care 1996; 12: 52-61. (Pubitemid 26098453)
2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-951. (Pubitemid 37267172)
3. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.
4. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32: 356-366.
5. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996; 21: 267-275. (Pubitemid 26159822)
6. Robertson JM, Friedman EM, Rubin BK. Nasal and sinus disease in cystic fibrosis. Paediatr Respir Rev 2008; 9: 213-219.
7. Chernick WS, Barbero GJ. Composition of tracheo-bronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 1959; 24: 739-745.
8. Smith AL, Redding G, Doershuk C, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988; 112: 547-554.
9. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 2003; 4: 8.
10. Jones AP, Wallis CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003; CD001127.
11. Frederiksen B, Pressler T, Hansen A, Koch C, Hoiby N. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 2006; 95: 1070-1074. (Pubitemid 44385111)
12. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642.
13. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-820.
14. Laube BL, Auci RM, Shields DE, et al. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996; 153: 752-760. (Pubitemid 26051359)
15. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 145-151.
16. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993; 342: 199-202. (Pubitemid 23214635)
17. Shah PI, Bush A, Canny GJ, Colin AA, et al. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. Eur Respir J 1995; 8: 954-958.
18. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 1996; 110: 889-895. (Pubitemid 26347599)
19. Robinson PJ: Dornase alfa in early cystic fibrosis lung disease. Pediatr Pulmonol 2002; 34: 237-241. (Pubitemid 34971080)
20. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008; 7: 523-530.
21. Arets HG, Brackel HJ, van der Ent CK. Forced expiratory manoeuvres in children: do they meet ATS and ERS criteria for spirometry? Eur Respir J 2001; 18: 655-660.
22. Zapletal A, Samanek M, Paul T: Lung function in children and adolescents. Methods, reference values. In: Zapletal A, ed. Progress in Respiration Research. Basel, Switzerland, Karger, 1987; 22: 114-218.
23. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001.
24. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003; 361: 681-689.
25. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-9192. (Pubitemid 120030590)
26. Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996; 51: 119-125. (Pubitemid 26060647)
27. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169: 719-725.
28. Ciofu O, Fussing V, Bagge N, Koch C, Hoiby N. Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother 2001; 48: 391-396. (Pubitemid 32898810)
29. Johansen HK, Kovesi TA, Koch C, Corey M, Hoiby N, Levison H. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol 1998; 26: 89-96. (Pubitemid 28381469)
30. Monforte V, Roman A, Gavalda J, et al. Contamination of the nebulization systems used in the prophylaxis with amphotericin B nebulized in lung transplantation. Transplant Proc 2005; 37: 4056-4058. (Pubitemid 43015252)